AAIS
VRTX icon

ABN AMRO Investment Solutions’s Vertex Pharmaceuticals VRTX Stock Holding History

ABN AMRO Investment Solutions’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.5M Buy
68,216
+49,146
+258% +$22.9M 0.4% 53
2025
Q4 		$8.65M Sell
19,070
-106,890
-85% -$46.1M 0.13% 139
2025
Q3 		$49.3M Sell
125,960
-4,331
-3% -$1.81M 1.01% 28
2025
Q2 		$58M Sell
130,291
-7,351
-5% -$3.39M 1.16% 24
2025
Q1 		$66.7M Sell
137,642
-2,595
-2% -$1.21M 1.39% 18
2024
Q4 		$56.5M Buy
140,237
+130,033
+1,274% +$60.3M 1.05% 25
2024
Q3 		$4.75M Sell
10,204
-3,424
-25% -$1.64M 0.08% 163
2024
Q2 		$6.39M Sell
13,628
-2,106
-13% -$914K 0.12% 132
2024
Q1 		$6.58M Sell
15,734
-10,950
-41% -$4.63M 0.11% 133
2023
Q4 		$10.9M Sell
26,684
-1,791
-6% -$662K 0.19% 102
2023
Q3 		$9.9M Sell
28,475
-1,387
-5% -$485K 0.19% 107
2023
Q2 		$10.5M Sell
29,862
-5,337
-15% -$1.8M 0.21% 106
2023
Q1 		$11.1M Buy
+35,199
New +$10.6M 0.23% 105

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ABN AMRO Investment Solutions's VRTX Position: Q1 2026 in Review

ABN AMRO Investment Solutions increased its Vertex Pharmaceuticals (VRTX) stake by 258% in Q1 2026, buying an estimated $22.9M and bringing the position to 68,216 shares worth $30.5M. The position accounts for 0.4% of the portfolio, ranked #53.

ABN AMRO Investment Solutions first reported a position in VRTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $66.7M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • ABN AMRO Investment Solutions held 68,216 shares of Vertex Pharmaceuticals worth $30.5M as of Q1 2026.
  • ABN AMRO Investment Solutions bought 49,146 Vertex Pharmaceuticals shares in Q1 2026, an estimated $22.9M.
  • Vertex Pharmaceuticals made up 0.4% of ABN AMRO Investment Solutions's portfolio in Q1 2026, its #53 holding.
  • ABN AMRO Investment Solutions first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • ABN AMRO Investment Solutions's Vertex Pharmaceuticals position peaked at $66.7M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on ABN AMRO Investment Solutions's 13F filing for Q1 2026, filed 12 May 2026.